Analyzed interventions and the estimates used for the stage were interventions are applied to.

a<p>Case Fatality - Estimates for stages III and IV are from Groot et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Groot1" target="_blank">[7]</a> and for stages I and II from Zelle et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Zelle1" target="_blank">[22]</a>. The CFs for the untreated patients are from Groot et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Groot1" target="_blank">[7]</a> and were corrected based on Bloom et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Bloom1" target="_blank">[57]</a>.</p>b<p>Disability Weights - Estimates from Zelle et al.<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Zelle1" target="_blank">[22]</a>.</p>c<p>Current stage distribution CR is based on Ortiz <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Ortiz1" target="_blank">[24]</a>; MX onKnaul et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Knaul2" target="_blank">[17]</a>; Effects of MAR derived from Devi <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Devi1" target="_blank">[50]</a>; Effects of screening interventions were based on stage shifts from baseline Groot et al.<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Groot1" target="_blank">[7]</a> to the stage distribution USA in Bland et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Bland1" target="_blank">[58]</a>. Stage shifts were adapted by calculating relative differences in detection rates between the USA and CR/MX from Duffy & Gabe <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Duffy1" target="_blank">[59]</a>. Calculations included age-specific incidence (MoH CR & Unidad Analysis Económica MX), prevalence (WHO 2008), sojourn time Duffy & Gabe <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Duffy1" target="_blank">[59]</a>, sensitivity Bobo et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Bobo1" target="_blank">[60]</a> and attendance rates (75% in the USA vs. 80% in Costa Rica and Mexico).</p>d<p>We assumed in Mexico implementing MAR could not lead to a higher proportion of stage IV patients and increase stage III with the difference of 0.6%.